PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis.
Panigrahy D,
Singer S,
Shen LQ,
Butterfield CE,
Freedman DA,
Chen EJ,
Moses MA,
Kilroy S,
Duensing S,
Fletcher C,
Fletcher JA,
Hlatky L,
Hahnfeldt P,
Folkman J,
Kaipainen A.
Surgical Research Laboratory, Children's Hospital, Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA.
Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects. Our study focuses on the PPARgamma ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes. We demonstrate, for the first time to our knowledge, that PPARgamma is highly expressed in tumor endothelium and is activated by rosiglitazone in cultured endothelial cells. Furthermore, we show that rosiglitazone suppresses primary tumor growth and metastasis by both direct and indirect antiangiogenic effects. Rosiglitazone inhibits bovine capillary endothelial cell but not tumor cell proliferation at low doses in vitro and decreases VEGF production by tumor cells. In our in vivo studies, rosiglitazone suppresses angiogenesis in the chick chorioallantoic membrane, in the avascular cornea, and in a variety of primary tumors. These results suggest that PPARgamma ligands may be useful in treating angiogenic diseases such as cancer by inhibiting angiogenesis.
PMID: 12370270 [PubMed - indexed for MEDLINE]
PMCID: PMC151148